Have a feature idea you'd love to see implemented?
Let us know!
CTSO Cytosorbents Corp
Price (delayed)
$0.89
Market cap
$48.66M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.36
Enterprise value
$62.87M
CytoSorbents Corporation is a leader in critical care immunotherapy, specializing in blood purification. Its flagship product, CytoSorb® is approved in the European Union with distribution in 66 countries around the
Highlights
The quick ratio has soared by 64% YoY
CTSO's EPS is up by 32% from the previous quarter and by 32% YoY
The debt has increased by 47% year-on-year
The equity has declined by 30% year-on-year and by 22% since the previous quarter
Key stats
What are the main financial stats of CTSO
Market
Valuations
Earnings
Shares outstanding
54.68M
Market cap
$48.66M
Enterprise value
$62.87M
Price to earnings (P/E)
N/A
Price to book (P/B)
3.73
Price to sales (P/S)
1.28
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.67
Revenue
$37.74M
EBIT
-$18.66M
EBITDA
-$16.55M
Free cash flow
-$18.8M
Per share
Balance sheet
Liquidity
EPS
-$0.36
Free cash flow per share
-$0.35
Book value per share
$0.24
Revenue per share
$0.69
TBVPS
$0.88
Total assets
$47.8M
Total liabilities
$34.8M
Debt
$26.37M
Equity
$13M
Working capital
$8.17M
Debt to equity
2.03
Current ratio
1.97
Quick ratio
2.23
Net debt/EBITDA
-0.86
Margins
Efficiency
Dividend
EBITDA margin
-43.8%
Gross margin
62.7%
Net margin
-49.5%
Operating margin
-58.5%
Return on assets
-37.1%
Return on equity
-103.8%
Return on invested capital
-39.3%
Return on capital employed
-47.4%
Return on sales
-49.4%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CTSO stock price
How has the Cytosorbents stock price performed over time
Intraday
-2.83%
1 week
-6.31%
1 month
-15.24%
1 year
-31.54%
YTD
-19.82%
QTD
-40.67%
Financial performance
How have Cytosorbents's revenue and profit performed over time
Revenue
$37.74M
Gross profit
$23.67M
Operating income
-$22.08M
Net income
-$18.67M
Gross margin
62.7%
Net margin
-49.5%
The net margin has increased by 28% since the previous quarter and by 22% year-on-year
CTSO's net income is up by 27% since the previous quarter and by 20% year-on-year
Cytosorbents's operating margin has increased by 23% YoY and by 13% QoQ
CTSO's operating income is up by 22% year-on-year and by 12% since the previous quarter
Growth
What is Cytosorbents's growth rate over time
Valuation
What is Cytosorbents stock price valuation
P/E
N/A
P/B
3.73
P/S
1.28
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.67
CTSO's EPS is up by 32% from the previous quarter and by 32% YoY
CTSO's P/B is 42% lower than its 5-year quarterly average of 6.4 but 10% higher than its last 4 quarters average of 3.4
The equity has declined by 30% year-on-year and by 22% since the previous quarter
The stock's price to sales (P/S) is 73% less than its 5-year quarterly average of 4.8 and 15% less than its last 4 quarters average of 1.5
Efficiency
How efficient is Cytosorbents business performance
The ROIC has grown by 32% from the previous quarter and by 27% YoY
CTSO's ROS is up by 30% from the previous quarter and by 25% YoY
The ROA has increased by 27% QoQ and by 13% YoY
The ROE has grown by 21% from the previous quarter but it has contracted by 18% YoY
Dividends
What is CTSO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CTSO.
Financial health
How did Cytosorbents financials performed over time
The company's total assets is 37% higher than its total liabilities
The quick ratio has soared by 64% YoY
CTSO's current ratio is up by 22% year-on-year but it is down by 7% since the previous quarter
The debt is 103% greater than the equity
The debt to equity has soared by 109% year-on-year and by 29% since the previous quarter
The debt has increased by 47% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.